About Fabricagen
We are building an antibody company around designed pharmacology.
Fabricagen creates and advances therapeutic antibody assets designed around the biology of disease.
Computational design and functional screening operate as one program engine. The objective is not software output. It is better therapeutic assets.
01
Pharmacology beyond affinity
Binding is necessary. The biological response determines whether a molecule can become a useful drug.
02
Data compounds
Each internal program creates sequence-function data that improves future design decisions.
03
Own the outcome
We use the engine to create and advance Fabricagen-owned therapeutic programs.
Team
Michael R. Holden, PhD
Founder & CEO
Michael built both the model and the assay.
PhD in Biochemistry, University of Denver (2018). Postdoc at the University of Colorado School of Medicine.
Prothena, antibody discovery across tau, alpha-synuclein and TDP-43. Regeneron, Principal Scientist leading an antibody engineering team. BioLoomics, Head of Chemistry, where he built the antibody-to-ADC workflow that produced 2,500 antibodies and 1,000 conjugates in one year.
Eight peer-reviewed publications.
Mike Minson, PhD
Founding Scientist · Joining Following Financing
Mike is expected to lead wet-lab development following financing. Seven years of in vitro assay development.
PhD, University of Colorado Boulder (2019).
ArcherDx, NGS assay design supporting an FDA submission. Sartorius, antibody and exosome platforms. BioLoomics, synthetic-biology lead, where he built the platform behind the company's $8M raise.
His bispecific binder against RBX1 was one of nine confirmed binders out of 322 designs in the GEM-X / Adaptyv competition, at 180 nM Kd.